门诊中脂肪性肝病的处理方法：诊断、管理及建议的命名法。
Approach to steatotic liver disease in the office: Diagnosis, management, and proposed nomenclature.
作者信息
Szilagyi Andrew, Hilzenrat Nir
机构信息
Honorary member of Jewish General Hospital at McGill University in Montréal, Que.
Researcher and clinical hepatologist at Jewish General Hospital and Associate Professor at McGill University.
出版信息
Can Fam Physician. 2025 Apr;71(4):249-254. doi: 10.46747/cfp.7104249.
OBJECTIVE
To provide an update on the most recent developments regarding diagnosis and outcomes of steatotic liver disease (SLD), review new nomenclature applied to SLD, and provide an approach to the diagnosis and management of SLD.
SOURCES OF INFORMATION
Individual articles published mainly in the past 2 years, found using PubMed and Google Scholar.
MAIN MESSAGE
Steatotic liver disease is one of the most common diseases encountered in general practice. This condition is an important biological marker for metabolic syndrome. Diagnosis relies on noninvasive tests. Known complications of metabolic syndrome and advanced liver disease are often present at the time of diagnosis. Courses of action should include assessment of cardiometabolic risk factors and progressive liver dysfunction. Subtle differences are present among patients diagnosed with SLD. Practitioners should be aware of a flux in terminology of SLD. Management of SLD can be guided using a simple algorithm.
CONCLUSION
There is a need for evaluation of the SLD epidemic and its systemic nature, along with associated independent risk factors of cardiovascular disease as well as metabolic conditions such as dyslipidemia, hypertension, and type 2 diabetes.
目的
提供有关脂肪性肝病（SLD）诊断和预后的最新进展，回顾应用于SLD的新命名法，并提供SLD的诊断和管理方法。
信息来源
主要通过使用PubMed和谷歌学术搜索过去2年发表的个别文章。
主要信息
脂肪性肝病是全科医疗中最常见的疾病之一。这种情况是代谢综合征的重要生物学标志物。诊断依赖于非侵入性检查。代谢综合征和晚期肝病的已知并发症在诊断时往往已经存在。行动方案应包括评估心脏代谢危险因素和进行性肝功能障碍。被诊断为SLD的患者之间存在细微差异。从业者应了解SLD术语的变化。可以使用简单的算法指导SLD的管理。
结论
需要评估SLD的流行情况及其系统性本质，以及心血管疾病的相关独立危险因素以及血脂异常、高血压和2型糖尿病等代谢状况。
Zotero 插件